Table 1 Summary of the cytogenetic findings in the seven samples of the patient

27.05.2010

47,XX,t(12;14)(q23.2;q32.3),+der(12)t(12;14)[9]/46,XX[11].

nuc ish(ATM,TP53)×2[204],(D12Z1x3,D13S319x1,LAMP1×2)[158/230],(5’IGHx3,3’IGH×2)(5’IGH sep 3’IGHx1)[167/216]

80% BM infiltration, fludarabine resistance, thrombopenia, therapy switch to rituximab and bendamustine

21.03.2011

47,XX,t(12;14)(q23.2;q32.3),+der(12)t(12;14)[7].ish der(12)t(12;14)(q23.2;q32.3)x2(5’IGH+).

nuc ish(D12Z1x3,D13S319x1,LAMP1x2)[91/212], (5’IGHx3,3’IGHx2)(5’IGH sep 3’IGHx1)[91/223]

Thrombocytopenia, 40% BM infiltration

24.10.2011

47,XX,t(12;14)(q23.2;q32.3),+der(12)t(12;14)[17]/46,XX[5]

Rituximab and bendamustine

14.03.2012

47,XX,t(12;14)(q23.2;q32.3),+der(12)t(12;14)[19]/46,XX[1]

95% BM infiltration

11.03.2013

45~47,XX,del(3)(p21),t(12;14)(q23.2;q32.3),+der(12)t(12;14),-13,add(17)(p11.2)[cp8]/46,XX[3].

nuc ish(ATMx2,TP53x1)[121/169],(D12Z3x3,D13S319x0,LAMP1x1)[146/217]/

(D12Z3x3,D13S319x1,LAMP1x1)[17/217]

85% BM infiltration, progression despite therapy with Ibrutinib, lymphadenopathy

03.09.2013

47,XX,t(12;14)(q23.2;q32.3),+der(12)t(12;14)[5]/46,idem,del(3)(p21),-13,add(17)(p11.2)[3]/46,XX[3]

80% BM infiltration, Alemtuzumab

09.01.2014

47,XX,t(12;14)(q23.2;q32.3),+der(12)t(12;14)[7]/46,idem,del(3)(p21),-13,add(17)(p11.2)[2]/46,XX[6]

96% BM infiltration, sample for expression microarray received